Stiolto Respimat

Showing 1 posts of 1 posts found.


Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD

January 15, 2019
Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma

Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …

Latest content